Can a simple blood test predict lung Cancer's next move?
NCT ID NCT05415358
First seen Feb 03, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This study looks at 23 people with advanced non-small cell lung cancer who have finished at least 20 months of immunotherapy. Researchers will collect blood and tissue samples to see if certain immune markers can predict whether the cancer will come back within 6 months. The goal is to better understand who might need extra monitoring after treatment ends.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atrium Health Levine Cancer
Charlotte, North Carolina, 28204, United States
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors know which patients are at risk of their lung cancer returning after stopping immunotherapy, allowing for closer monitoring or earlier treatment.
What could go wrong
This is a small, early-stage study with only 23 participants, so results may not apply to everyone. It is observational and does not test a new treatment, so it won't directly change care yet.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.